welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- log in
First Patient Dosed in Phase II Clinical Trial in Duchenne Muscular Dystrophy
Antisense Therapeutics today announced dosing of the first patient in a Phase II clinical trial of its immunomodulatory therapy, ATL1102, in patients with Duchenne Muscular Dystrophy (DMD).
Commencement of the trial represents an important development milestone for the Company and for patients seeking better and safer treatments.
ATL1102 is an inhibitor of CD49d expression on certain immune cells (T cells). DMD patients who have a greater number of T cells with high levels of CD49d on their surface have more severe and rapid disease progression.
rareRelated
-
Long-Term Outcomes of Ataluren in Duchenne Muscular DystrophyThis study is a long-term study of atalu...
-
Santhera to Discontinue Phase 3 SIDEROS Study and Development of Puldysa® in Duchenne Muscular Dystrophy (DMD) and ...Santhera Pharmaceuticals announces the d...
-
Enhanced CRISPR-Cas9 Correction of Duchenne Muscular Dystrophy in Mice by a Self-Complementary AAV Delivery SystemDuchenne muscular dystrophy (DMD) is a l...
-
Edasalonexent could reduce functional decline in boys with DMD, MoveDMD phase 2 results suggestResults of the Phase 2 MoveDMD trial sho...
-
Efficacy, Safety, and Tolerability Rollover Study of Eteplirsen in Subjects With Duchenne Muscular DystrophyThe primary objective of this study is t...
-
Exon Skipping and Stop Codon Read-ThroughThe DMD gene is made up of 79 pieces cal...
-
Capricor places Duchenne drug trial on holdCapricor Therapeutics Inc said on Wednes...
